TCT 2021: FAME3: PCI Guided by FFR Didn't Meet Noninferiority for 1Y Outcomes Compared to CABG

Подробнее о видео

Watch the full video on Radcliffe Cardiology here:

In this short interview, Dr William F Fearon (Stanford University School of Medicine, US) discusses the findings from the FAME3 trial. This multicenter, international, randomized, controlled noninferiority trial investigated whether fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease (CAD) will result in similar outcomes to coronary artery bypass graft surgery (CABG).
Presented first at TCT 2021, study finds that PCI guided by FFR did not meet noninferiority for one-year outcomes compared to bypass surgery.

Discussion Points:
Importance of the Trial
Study Design
Key Findings
Implications for Clinical Practice
Who Would Benefit from FFR-guided PCI
Next Steps

Recorded remotely from Stanford, 2021.

Radcliffe Cardiology is a dynamic, digitally-focused producer & publisher of Cardiovascular, Renal and Metabolic (CVRM) content for physicians worldwide. We aim to assist in the continuous education of physicians within the cardiology fraternity, generating a range of clinical content through collaboration with leading cardiologists from around the globe.